Department of Urology Surgery, The First Hospital of Jilin University, Changchun, P.R. China.
Department of Thoracic Surgery, The First Hospital of Jilin University, Changchun, P.R. China.
Medicine (Baltimore). 2022 Sep 9;101(36):e30380. doi: 10.1097/MD.0000000000030380.
Systemic Immune-inflammation Index (SII) has been shown to correlate with the prognosis of numerous malignancies, but researchers have not yet reached an agreed conclusion on bladder cancer. To fill the blank, we conducted a meta-analysis to assess the prognostic role of SII in the prognosis of bladder cancer.
After analyzing relevant literature published in PubMed, China National Knowledge Infrastructure, EMBASE, Cochrane Library, and Web Science up to April 30, 2022, we collected 83 articles to assess the significance of SII levels in assessing the prognosis of bladder cancer patients, and finally, 11 articles were included in the study. The correlation between pre-treatment Systemic Immunoinflammatory Index levels and survival in bladder cancer patients was assessed using risk ratio (HR) and 95% confidence interval (CI).
Our meta-analysis comprised 11 papers altogether, and the findings revealed that higher levels of pretreatment SII were significantly associated with poorer overall survival/cancer-specific survival/progression-free survival/recurrence-free survival in bladder cancer patients (pooled HR = 1.80; 95% CI, 1.28-2.51; pooled HR = 1.68; 95% CI, 1.14-2.47; pooled HR = 1.74; 95% CI, 1.25-2.42; pooled HR = 1.73; 95% CI, 1.26-2.39). The above result was also confirmed in the subgroup analysis.
Higher SII levels were significantly connected with overall survival/cancer-specific survival/progression-free survival/recurrence-free survival rates in bladder cancer patients, suggesting that SII is an important predictor of prognosis in bladder cancer patients.
全身性免疫炎症指数（SII）已被证明与许多恶性肿瘤的预后相关，但研究人员尚未就膀胱癌达成一致结论。为了填补这一空白，我们进行了一项荟萃分析，以评估 SII 在膀胱癌预后中的预测作用。
通过分析截至 2022 年 4 月 30 日在 PubMed、中国国家知识基础设施、EMBASE、Cochrane 图书馆和 Web Science 上发表的相关文献，我们共收集了 83 篇文章，以评估 SII 水平在评估膀胱癌患者预后中的意义，最终有 11 篇文章纳入研究。使用风险比（HR）和 95%置信区间（CI）评估膀胱癌患者治疗前 SII 水平与生存的相关性。
我们的荟萃分析共包括 11 篇论文，结果表明，膀胱癌患者治疗前 SII 水平较高与总体生存/癌症特异性生存/无进展生存/无复发生存较差显著相关（合并 HR = 1.80；95%CI，1.28-2.51；合并 HR = 1.68；95%CI，1.14-2.47；合并 HR = 1.74；95%CI，1.25-2.42；合并 HR = 1.73；95%CI，1.26-2.39）。亚组分析也证实了上述结果。
较高的 SII 水平与膀胱癌患者的总体生存/癌症特异性生存/无进展生存/无复发生存率显著相关，提示 SII 是膀胱癌患者预后的一个重要预测因素。
